Top

Published in:

01-08-2014 | Breast Oncology

Sentinel Lymph Node Biopsy in Pregnant Women with Breast Cancer

Authors: Adrienne B. Gropper, MD, Katherina Zabicki Calvillo, MD, Laura Dominici, MD, Susan Troyan, MD, Esther Rhei, MD, Katherine E. Economy, MD, Nadine M. Tung, MD, Lidia Schapira, MD, Jane L. Meisel, MD, Ann H. Partridge, MD, MPH, Erica L. Mayer, MD, MPH

Published in: Annals of Surgical Oncology | Issue 8/2014

Abstract

Background

Sentinel lymph node biopsy (SNB) in pregnant women with breast cancer is uncommonly pursued given concern for fetal harm. This study evaluated efficacy and safety outcomes in pregnant breast cancer patients undergoing SNB.

Methods

Patients who underwent SNB while pregnant were identified from a retrospective parent cohort of women diagnosed with breast cancer during pregnancy. Chart review was performed to tabulate patient/tumor characteristics, method/outcome of SNB, and short-term maternal/fetal outcomes.

Results

Within a cohort of 81, 47 clinically node-negative patients had surgery while pregnant: 25 (53.2 %) SNB, 20 (42.6 %) upfront axillary lymph node dissection, and 2 (4.3 %) no lymph node surgery. Of SNB patients, 8, 9, and 8 had SNB in the first, second, and third trimesters, respectively. 99 m-Technetium (99-Tc) alone was used in 16 patients, methylene blue dye alone in 7 patients, and 2 patients had unknown mapping method. Mapping was successful in all patients. There were no SNB-associated complications. At a median of 2.5 years from diagnosis, there was one locoregional recurrence, one new primary contralateral tumor, three distant recurrences, and one breast cancer death. Among patients who underwent SNB, there were 25 liveborn infants, of whom 24 were healthy, and 1 had cleft palate (in the setting of other maternal risk factors).

Conclusions

SNB in pregnant breast cancer patients appears to be safe and accurate using either methylene blue or 99-Tc. This is one of the largest reported experiences of SNB during pregnancy; however, numbers remain limited. SNB rates in this cohort were lower than in non-pregnant breast cancer patients.

Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). J Natl Cancer Inst. 2008;100:462–474.PubMedCrossRef

Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–933.PubMedCentralPubMedCrossRef

Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595–600.PubMedCrossRef

Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–575.PubMedCrossRef

Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–553.PubMedCrossRef

Guidroz JA, Scott-Conner CE, Weigel RJ. Management of pregnant women with breast cancer. J Surg Oncol. 2011;103:337–340.PubMedCrossRef

Rodriguez AO, Chew H, Cress R, Xing G, McElvy S, Danielsen B, Smith L. Evidence of poorer survival in pregnancy-associated breast cancer. Obstet Gynecol. 2008;112:71–78.PubMedCrossRef

Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer. 2006;106:237–246.PubMedCrossRef

Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94:2542–2551.

10.

Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–7720.PubMedCrossRef

11.

Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging. 2010;37:78–83.PubMedCrossRef

12.

Spanheimer PM, Graham MM, Sugg SL, Scott-Conner CE, Weigel RJ. Measurement of uterine radiation exposure from lymphoscintigraphy indicates safety of sentinel lymph node biopsy during pregnancy. Ann Surg Oncol. 2009;16:1143–1147.PubMedCrossRef

13.

Dubernard G, Garbay JR, Rouzier R, Delaloge S. Safety of sentinel node biopsy in pregnant patients. Ann Oncol. 2005;16:987;987–988.

14.

Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg. 2003;138:91–98; discussion 99.

15.

Meisel JL, Economy KE, Calvillo KZ, et al. Contemporary multidisciplinary treatment of pregnancy-associated breast cancer. Springerplus. 2013;2:297.PubMedCentralPubMedCrossRef

16.

Mondi MM, Cuenca RE, Ollila DW, Stewart JH 4th, Levine EA. Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surg Oncol. 2007;14:218–221.PubMedCrossRef

17.

Khera SY, Kiluk JV, Hasson DM, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. 2008;14:250–254.PubMedCrossRef

18.

Andtbacka RH, Donaldson MR, Bowles TL, et al. Sentinel lymph node biopsy for melanoma in pregnant women. Ann Surg Oncol. 2013;20:689–696.PubMedCrossRef

19.

Pandit-Taskar N, Dauer LT, Montgomery L, St Germain J, Zanzonico PB, Divgi CR. Organ and fetal absorbed dose estimates from 99 mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med. 2006;47:1202–1208.PubMed

20.

Gentilini O, Cremonesi M, Trifiro G, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004;15:1348–1351.PubMedCrossRef

21.

Keleher A, Wendt R 3rd, Delpassand E, Stachowiak AM, Kuerer HM. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004;10:492–495.PubMedCrossRef

22.

Cimmino VM, Brown AC, Szocik JF, Pass HA, Moline S, De SK, et al. Allergic reactions to isosulfan blue during sentinel node biopsy: a common event. Surgery. 2001;130:439–442.PubMedCrossRef

23.

Albo D, Wayne JD, Hunt KK, et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg. 2001;182:393–398.PubMedCrossRef

24.

Masannat YA, Hanby A, Horgan K, Hardie LJ. DNA damaging effects of the dyes used in sentinel node biopsy: possible implications for clinical practice. J Surg Res. 2009;154:234–238.PubMedCrossRef

25.

Pruthi S, Haakenson C, Brost BC, et al. Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancer-implications for use in pregnancy. Am J Surg. 2011;201:70–75.PubMedCrossRef

26.

Cody HS 3rd, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol. 2001;8:13–19.PubMedCrossRef

27.

Pesek S, Ashikaga T, Krag LE, Krag D. The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg. 2012;36:2239–2251.PubMedCentralPubMedCrossRef

28.

Keleher AJ, Theriault RL, Gwyn KM, et al. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg. 2002;194:54–64.PubMedCrossRef

29.

Amant F, von Minckwitz G, Han SN, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013;31:2532–2539.PubMedCrossRef

30.

Theriault RL, Litton JK. Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know? J Clin Oncol. 2013;31:2521–2522.PubMedCrossRef

31.

Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer. 2003;98:1055–1060.PubMedCrossRef

32.

Rutgers EJ, Donker M, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: final analysis of the EORTC AMAROS trial [abstract no. LBA1001]. J Clin Oncol. 2013;31 Suppl.

Title: Sentinel Lymph Node Biopsy in Pregnant Women with Breast Cancer
Authors: Adrienne B. Gropper, MD
Katherina Zabicki Calvillo, MD
Laura Dominici, MD
Susan Troyan, MD
Esther Rhei, MD
Katherine E. Economy, MD
Nadine M. Tung, MD
Lidia Schapira, MD
Jane L. Meisel, MD
Ann H. Partridge, MD, MPH
Erica L. Mayer, MD, MPH
Publication date: 01-08-2014
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 8/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-3718-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Sentinel Lymph Node Biopsy in Pregnant Women with Breast Cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2014

Should Stage T2 Esophageal Squamous Cell Carcinoma Be Subclassified?

Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial

The Pregnant Breast Cancer Patient: Are We Failing Our Most Vulnerable Population?

Gastric Stump Cancer After Distal Gastrectomy for Benign Disease: Clinicopathological Features and Surgical Outcomes

Clinicopathology and Genetic Profile of Synchronous Multiple Small Adenocarcinomas: Implication for Surgical Treatment of an Uncommon Lung Malignancy

Prognostic Significance of Non-curative Gastrectomy for Incurable Gastric Carcinoma